Seroprevalence of SARS-CoV-2 in four states of Nigeria in October 2020: A population-based household survey
Author
Audu, Rosemary A.Stafford, Kristen A.
Steinhardt, Laura
Musa, Zaidat A.
Iriemenam, Nnaemeka
Ilori, Elsie
Blanco, Natalia
Mitchell, Andrew
Hamada, Yohhei
Moloney, Mirna
Iwara, Emem
Abimiku, Alash’le
Ige, Fehintola A.
William, Nwachukwu E.
Igumbor, Ehimario
Ochu, Chinwe
Omoare, Adesuyi A.
Okunoye, Olumide
Greby, Stacie M.
Rangaka, Molebogeng X.
Copas, Andrew
Dalhatu, Ibrahim
Abubakar, Ibrahim
McCracken, Stephen
Alagi, Matthias
Mba, Nwando
Anthony, Ahumibe
Okoye, McPaul
Okoi, Catherine
Ezechi, Oliver C.
Salako, Babatunde L.
Ihekweazu, Chikwe
Date
2022-06-17Journal
PLoS ONEPublisher
Public Library of Science (PLoS)Type
Article
Metadata
Show full item recordAbstract
The observed epidemiology of SARS-CoV-2 in sub-Saharan Africa has varied greatly from that in Europe and the United States, with much lower reported incidence. Population-based studies are needed to estimate true cumulative incidence of SARS-CoV-2 to inform public health interventions. This study estimated SARS-CoV-2 seroprevalence in four selected states in Nigeria in October 2020. We implemented a two-stage cluster sample household survey in four Nigerian states (Enugu, Gombe, Lagos, and Nasarawa) to estimate age-stratified prevalence of SARS-CoV-2 antibodies. All individuals in sampled households were eligible for interview, blood draw, and nasal/oropharyngeal swab collection. We additionally tested participants for current/recent malaria infection. Seroprevalence estimates were calculated accounting for the complex survey design. Across all four states, 10,629 (96·5%) of 11,015 interviewed individuals provided blood samples. The seroprevalence of SARS-CoV-2 antibodies was 25·2% (95% CI 21·8–28·6) in Enugu State, 9·3% (95% CI 7·0–11·5) in Gombe State, 23·3% (95% CI 20·5–26·4) in Lagos State, and 18·0% (95% CI 14·4–21·6) in Nasarawa State. Prevalence of current/recent malaria infection ranged from 2·8% in Lagos to 45·8% in Gombe and was not significantly related to SARS-CoV-2 seroprevalence. The prevalence of active SARS-CoV-2 infection in the four states during the survey period was 0·2% (95% CI 0·1–0·4). Approximately eight months after the first reported COVID-19 case in Nigeria, seroprevalence indicated infection levels 194 times higher than the 24,198 officially reported COVID-19 cases across the four states; however, most of the population remained susceptible to COVID-19 in October 2020.Sponsors
Center for Global HealthIdentifier to cite or link to this item
http://hdl.handle.net/10713/19249ae974a485f413a2113503eed53cd6c53
10.1371/journal.pgph.0000363
Scopus Count
Except where otherwise noted, this item's license is described as https://creativecommons.org/publicdomain/zero/1.0/